CL2013001322A1 - Metodo para tratar un cancer tal como cancer de ovario, endometrio o pulmon, que comprende las etapas de administrar ec145 y uno o mas agentes quimioterapeuticos como taxano, docetaxel y paclitaxel, estando ambos componentes en contenedores esteriles; y kit que comprende ec145 y uno o mas agentes quimioterapeuticos adicionales. - Google Patents

Metodo para tratar un cancer tal como cancer de ovario, endometrio o pulmon, que comprende las etapas de administrar ec145 y uno o mas agentes quimioterapeuticos como taxano, docetaxel y paclitaxel, estando ambos componentes en contenedores esteriles; y kit que comprende ec145 y uno o mas agentes quimioterapeuticos adicionales.

Info

Publication number: CL2013001322A1
Authority: CL; Chile
Prior art keywords: chemotherapeutic agents; cancer; taxane; docetaxel; endometrial
Prior art date: 2010-11-12

Application number

CL2013001322A

Other languages

English (en)

Inventor

Binh Nguyen

Joseph Anand Reddy

Christopher Paul Leamon

Original Assignee

Endocyte Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-12

Filing date

2013-05-13

Publication date

2014-03-28

2013-05-13 Application filed by Endocyte Inc filed Critical Endocyte Inc

2014-03-28 Publication of CL2013001322A1 publication Critical patent/CL2013001322A1/es

Links

239000002246 antineoplastic agent Substances 0.000 title 2
229940127089 cytotoxic agent Drugs 0.000 title 2
206010014733 Endometrial cancer Diseases 0.000 title 1
206010014759 Endometrial neoplasm Diseases 0.000 title 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
206010033128 Ovarian cancer Diseases 0.000 title 1
206010061535 Ovarian neoplasm Diseases 0.000 title 1
229930012538 Paclitaxel Natural products 0.000 title 1
229940123237 Taxane Drugs 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
229960003668 docetaxel Drugs 0.000 title 1
230000002357 endometrial effect Effects 0.000 title 1
208000020816 lung neoplasm Diseases 0.000 title 1
230000002611 ovarian Effects 0.000 title 1
229960001592 paclitaxel Drugs 0.000 title 1
DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Inorganic Chemistry (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Reproductive Health (AREA)
Food Science & Technology (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL2013001322A 2010-11-12 2013-05-13 Metodo para tratar un cancer tal como cancer de ovario, endometrio o pulmon, que comprende las etapas de administrar ec145 y uno o mas agentes quimioterapeuticos como taxano, docetaxel y paclitaxel, estando ambos componentes en contenedores esteriles; y kit que comprende ec145 y uno o mas agentes quimioterapeuticos adicionales. CL2013001322A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US41327510P	2010-11-12	2010-11-12

Publications (1)

Publication Number	Publication Date
CL2013001322A1 true CL2013001322A1 (es)	2014-03-28

Family

ID=46048353

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CL2013001324A CL2013001324A1 (es)	2010-11-12	2013-05-13	Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.
CL2013001322A CL2013001322A1 (es)	2010-11-12	2013-05-13	Metodo para tratar un cancer tal como cancer de ovario, endometrio o pulmon, que comprende las etapas de administrar ec145 y uno o mas agentes quimioterapeuticos como taxano, docetaxel y paclitaxel, estando ambos componentes en contenedores esteriles; y kit que comprende ec145 y uno o mas agentes quimioterapeuticos adicionales.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CL2013001324A CL2013001324A1 (es)	2010-11-12	2013-05-13	Kit que comprende ec145 y uno o mas agentes quimioterapéuticos adicionales; uso para tratar un cancer.

Country Status (15)

Country	Link
US (3)	US8883737B2 (es)
EP (2)	EP2638395A4 (es)
JP (2)	JP2013542264A (es)
KR (2)	KR20130140032A (es)
CN (2)	CN103282777A (es)
AU (2)	AU2011325989C1 (es)
BR (2)	BR112013011590A2 (es)
CA (2)	CA2817223A1 (es)
CL (2)	CL2013001324A1 (es)
EA (2)	EA025069B1 (es)
IL (2)	IL226247A0 (es)
MX (2)	MX2013005194A (es)
SG (2)	SG190245A1 (es)
WO (2)	WO2012065085A1 (es)
ZA (2)	ZA201304226B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101098854B (zh)	2004-07-23	2012-12-05	恩多塞特公司	二价连接体及其轭合物
US9877965B2 (en)	2007-06-25	2018-01-30	Endocyte, Inc.	Vitamin receptor drug delivery conjugates for treating inflammation
US9138484B2 (en)	2007-06-25	2015-09-22	Endocyte, Inc.	Conjugates containing hydrophilic spacer linkers
SG190245A1 (en)	2010-11-12	2013-06-28	Endocyte Inc	Methods of treating cancer
US20140030321A1 (en) *	2011-04-12	2014-01-30	Endocyte, Inc.	Solid pharmaceutical composition
WO2013126797A1 (en)	2012-02-24	2013-08-29	Purdue Research Foundation	Cholecystokinin b receptor targeting for imaging and therapy
US20140154702A1 (en) *	2012-11-30	2014-06-05	Endocyte, Inc.	Methods For Treating Cancer Using Combination Therapies
US11162937B2 (en)	2013-11-19	2021-11-02	Purdue Research Foundation	Patient selection method for inflammation
SMT202100191T1 (it)	2014-02-21	2021-05-07	Nektar Therapeutics	Agonisti selettivi per il-2rbeta in combinazione con un anticorpo anti.ctla-4 o un anticorpo anti-pd-1
CN103816548A (zh) *	2014-03-11	2014-05-28	北京林业大学	靶向亲水性聚合物-雷公藤甲素结合物
EP3125920B1 (en)	2014-04-04	2020-12-23	Del Mar Pharmaceuticals	Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
WO2015160833A1 (en) *	2014-04-14	2015-10-22	Endocyte, Inc.	Drug delivery conjugates for treating resistant cancer and for use in combination therapy
ES3014002T3 (en) *	2018-08-31	2025-04-16	Sun Pharmaceutical Ind Ltd	Parenteral dosage form of carboplatin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6441026B1 (en) *	1993-11-08	2002-08-27	Aventis Pharma S.A.	Antitumor compositions containing taxane derivatives
DE60326833D1 (de) *	2002-05-15	2009-05-07	Endocyte Inc	Vitamin-mitomycin-konjugate
US20060024692A1 (en) *	2002-09-30	2006-02-02	Oncotherapy Science, Inc.	Method for diagnosing non-small cell lung cancers
AR042942A1 (es)	2003-01-27	2005-07-06	Endocyte Inc	Conjugados de administracion de drogas de union de receptores de vitaminas
SI1592457T1 (sl)	2003-01-27	2012-12-31	Endocyte, Inc.	Konjugat folat-vinblastin kot zdravilo
WO2006105141A1 (en) *	2005-03-30	2006-10-05	Purdue Research Foundation	Method for cancer prognosis using cellular folate vitamin receptor quantification
WO2007022493A2 (en) *	2005-08-19	2007-02-22	Endocyte, Inc.	Ligand conjugates of vinca alkaloids, analogs, and derivatives
US20070065449A1 (en) *	2005-09-16	2007-03-22	Claire Verschraegen	Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
US9138484B2 (en)	2007-06-25	2015-09-22	Endocyte, Inc.	Conjugates containing hydrophilic spacer linkers
AU2009293140A1 (en) *	2008-09-17	2010-03-25	Endocyte, Inc.	Folate receptor binding conjugates of antifolates
CN102301002A (zh) *	2008-11-12	2011-12-28	卡里斯生命科学卢森堡控股有限责任公司	使用外来体来确定表现型的方法和系统
WO2011014821A1 (en)	2009-07-31	2011-02-03	Endocyte, Inc.	Folate-targeted diagnostics and treatment
SG190245A1 (en)	2010-11-12	2013-06-28	Endocyte Inc	Methods of treating cancer

2011
- 2011-11-11 SG SG2013036306A patent/SG190245A1/en unknown
- 2011-11-11 EA EA201390694A patent/EA025069B1/ru not_active IP Right Cessation
- 2011-11-11 AU AU2011325989A patent/AU2011325989C1/en not_active Ceased
- 2011-11-11 BR BR112013011590A patent/BR112013011590A2/pt not_active IP Right Cessation
- 2011-11-11 CA CA2817223A patent/CA2817223A1/en not_active Abandoned
- 2011-11-11 SG SG2013036280A patent/SG190244A1/en unknown
- 2011-11-11 KR KR1020137013270A patent/KR20130140032A/ko not_active Ceased
- 2011-11-11 EA EA201390695A patent/EA026168B1/ru not_active IP Right Cessation
- 2011-11-11 CA CA2817219A patent/CA2817219A1/en not_active Abandoned
- 2011-11-11 JP JP2013538939A patent/JP2013542264A/ja active Pending
- 2011-11-11 US US13/884,842 patent/US8883737B2/en not_active Expired - Fee Related
- 2011-11-11 CN CN2011800634321A patent/CN103282777A/zh active Pending
- 2011-11-11 EP EP11839397.4A patent/EP2638395A4/en not_active Withdrawn
- 2011-11-11 BR BR112013011659A patent/BR112013011659A2/pt not_active IP Right Cessation
- 2011-11-11 US US13/294,624 patent/US8987281B2/en not_active Expired - Fee Related
- 2011-11-11 MX MX2013005194A patent/MX2013005194A/es unknown
- 2011-11-11 CN CN201180061415.4A patent/CN103403552B/zh not_active Expired - Fee Related
- 2011-11-11 MX MX2013005196A patent/MX2013005196A/es unknown
- 2011-11-11 JP JP2013538937A patent/JP2013542263A/ja active Pending
- 2011-11-11 WO PCT/US2011/060407 patent/WO2012065085A1/en not_active Ceased
- 2011-11-11 WO PCT/US2011/060395 patent/WO2012065079A1/en not_active Ceased
- 2011-11-11 AU AU2011325982A patent/AU2011325982C1/en not_active Ceased
- 2011-11-11 KR KR1020137013272A patent/KR20130140033A/ko not_active Ceased
- 2011-11-11 EP EP11840607.3A patent/EP2638397A4/en not_active Withdrawn
2013
- 2013-03-13 US US13/800,254 patent/US20140066383A1/en not_active Abandoned
- 2013-05-09 IL IL226247A patent/IL226247A0/en unknown
- 2013-05-09 IL IL226246A patent/IL226246A0/en unknown
- 2013-05-13 CL CL2013001324A patent/CL2013001324A1/es unknown
- 2013-05-13 CL CL2013001322A patent/CL2013001322A1/es unknown
- 2013-06-10 ZA ZA2013/04226A patent/ZA201304226B/en unknown
- 2013-06-10 ZA ZA2013/04225A patent/ZA201304225B/en unknown

Also Published As

Publication number	Publication date
EP2638395A4 (en)	2016-06-01
KR20130140032A (ko)	2013-12-23
WO2012065085A1 (en)	2012-05-18
CA2817223A1 (en)	2012-05-18
ZA201304225B (en)	2018-05-30
HK1189272A1 (zh)	2014-05-30
BR112013011659A2 (pt)	2016-08-02
US20130330326A1 (en)	2013-12-12
US8987281B2 (en)	2015-03-24
AU2011325989A1 (en)	2013-04-11
SG190244A1 (en)	2013-06-28
EP2638397A4 (en)	2016-06-01
US20120122893A1 (en)	2012-05-17
EA201390695A1 (ru)	2013-12-30
WO2012065085A4 (en)	2012-07-12
BR112013011590A2 (pt)	2019-09-24
EP2638397A1 (en)	2013-09-18
AU2011325989B2 (en)	2014-10-09
CN103403552A (zh)	2013-11-20
IL226246A0 (en)	2013-07-31
EP2638395A1 (en)	2013-09-18
MX2013005196A (es)	2013-06-28
CL2013001324A1 (es)	2014-05-16
ZA201304226B (en)	2017-11-29
WO2012065079A1 (en)	2012-05-18
CN103403552B (zh)	2016-01-06
JP2013542264A (ja)	2013-11-21
US8883737B2 (en)	2014-11-11
AU2011325982A1 (en)	2013-04-18
CN103282777A (zh)	2013-09-04
SG190245A1 (en)	2013-06-28
AU2011325982C1 (en)	2015-08-20
WO2012065079A4 (en)	2012-07-12
EA201390694A1 (ru)	2013-12-30
AU2011325989C1 (en)	2015-04-23
US20140066383A1 (en)	2014-03-06
AU2011325982B2 (en)	2014-10-09
CA2817219A1 (en)	2012-05-18
EA026168B1 (ru)	2017-03-31
EA025069B1 (ru)	2016-11-30
JP2013542263A (ja)	2013-11-21
IL226247A0 (en)	2013-06-27
KR20130140033A (ko)	2013-12-23
MX2013005194A (es)	2013-06-28

Publication	Publication Date	Title
CL2013001322A1 (es)	2014-03-28	Metodo para tratar un cancer tal como cancer de ovario, endometrio o pulmon, que comprende las etapas de administrar ec145 y uno o mas agentes quimioterapeuticos como taxano, docetaxel y paclitaxel, estando ambos componentes en contenedores esteriles; y kit que comprende ec145 y uno o mas agentes quimioterapeuticos adicionales.
HK1216853A1 (zh)	2016-12-09	治療胰腺癌的方法
BR112015006996A2 (pt)	2017-07-04	método para reduzir a quantidade de enxofre em uma composição que compreende enxofre, e, composição.
BR112013014316A2 (pt)	2016-09-27	tratamento de câncer her2-positivo com paclitaxel e trastuzumabe-mcc-dm1
PL3958116T3 (pl)	2023-12-18	Graficzna jednostka obliczeniowa ogólnego przeznaczenia oraz sposób wykonywania instrukcji o mieszanej precyzji
BR112015002541A2 (pt)	2017-12-05	composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
NI201001032A (es)	2011-04-26	Formas crsitalinas de dimetoxi docetaxel y metodo para preparar el mismo.
IL221871A (en)	2017-03-30	Use of a medicament containing tetrahydrocannabinol, cannabidiol and temozolomide in the treatment of glioma
CL2011003350A1 (es)	2012-06-08	Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
EP2627358C0 (en)	2024-03-27	PRETARGETING KIT AND METHOD, AND AGENTS THEY USE
LT2340031T (lt)	2019-08-12	Gdf gaudyklės, skirtos naudoti anemijos gydymui
CL2014002549A1 (es)	2015-01-16	Anticuerpos anti-lgr5 e inmunoconjugados; formulacion farmaceutica que los contiene; metodo de tratamiento en los que se administra anticuerpos anti-lgr5 e inmunoconjugados.
CL2015001486A1 (es)	2015-10-16	Composición que comprende agentes de control biológico.
CO6620019A2 (es)	2013-02-15	Métodos de tratamiento de cander de vejiga
BR112014023937A2 (pt)	2018-04-17	composição farmacêutica, agente farmacêutico de combinação e método de tratamento
CL2013001009A1 (es)	2013-08-30	Compuestos heterociclicos fusionados; composicion farmaceutica que los comprende, y uso en el tratamiento de un trastorno proliferativo tal como cancer.
CL2013003349A1 (es)	2014-06-06	Composicion que comprende una combinacion sinergica de un fungicida polienico y por lo menos un lipopeptido; y metodo para controlar patogenos fungicos.
BR112013004456A2 (pt)	2016-06-07	composição para tratamento de planta, e, método para o tratamento de plantas
CL2014003271A1 (es)	2015-08-21	Composición que comprende un agente de control biológico y un fungicida.
BR112013014522A2 (pt)	2017-09-26	anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
BR112014005422A2 (pt)	2018-11-21	suplemento de micronutriente, e, método para fazer o mesmo
CL2014001719A1 (es)	2014-11-03	Metodo para tratar la perdida osea alveolar que comprende anticuerpo antiesclerostina.
BR112014012623A2 (pt)	2017-06-13	métodos para determinar adequação de terapia anticâncer, composição, kit e método para melhorar o efeito do tratamento de um regime quimioterápico
HUE063599T2 (hu)	2024-01-28	Eljárások ödémás fibroszklerotikus pannikulopátia kezelésére vagy csökkentésére
PL2632550T3 (pl)	2017-10-31	Sposoby i kompozycja do leczenia biegunki związanej z HIV